This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. McALLEN, Texas (Border Report) — A new study ...
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...
Site burden has always been a trending topic in clinical research. What is the impact on study startup? One major issue is that protocol design fails to consider site workflows. When trials are ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and ...
McALLEN, Texas (Border Report) — A new study says U.S. and Mexican collaboration is essential to halting illegal immigration at the border, and it credits Mexico for helping to reduce crossings at the ...
Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC, in ...
Entered into Clinical Study Collaboration and Supply Agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with sacituzumab-govitecan-hziy ("Trodelvy") Gilead's Trop-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results